Get the Stockscreener App
516.36
0.73%
-3.392
Madrigal Pharmaceuticals Inc stock is traded at $516.36, with a volume of 88,255.
It is down -0.73% in the last 24 hours and up +19.10% over the past month.
Madrigal Pharmaceuticals Inc is a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), a serious liver disease with high unmet medical need that can lead to cirrhosis, liver failure, liver cancer, need for liver transplantation and premature mortality. Its medication, Rezdiffra (resmetirom), is a once-daily, oral, liver-directed thyroid hormone receptor beta agonist designed to target key underlying causes of MASH.
See More
Previous Close:
$519.75
Open:
$516.96
24h Volume:
88,255
Relative Volume:
0.24
Market Cap:
$11.84B
Revenue:
$958.40M
Net Income/Loss:
$-288.28M
P/E Ratio:
-40.14
EPS:
-12.8641
Net Cash Flow:
$-193.02M
1W Performance:
-5.66%
1M Performance:
+19.10%
6M Performance:
+20.46%
1Y Performance:
+64.34%
1-Day Range:
$510.64
$523.55
1-Week Range:
$503.93
$547.18
52-Week Range:
$265.00
$615.00
Madrigal Pharmaceuticals Inc Stock (MDGL) Company Profile
Name
Madrigal Pharmaceuticals Inc
Sector
Industry
Phone
404-380-9263
Address
200 BARR HARBOR DRIVE, SUITE 400, WEST CONSHOHOCKEN, PA
Compare MDGL vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
MDGL
Madrigal Pharmaceuticals Inc
|
516.01 | 11.92B | 958.40M | -288.28M | -193.02M | -12.86 |
VRTX
Vertex Pharmaceuticals Inc
|
443.57 | 112.92B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
765.67 | 81.99B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
795.49 | 48.82B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
320.88 | 43.66B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
315.13 | 34.65B | 5.36B | 287.73M | 924.18M | 2.5229 |
Madrigal Pharmaceuticals Inc Stock (MDGL) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-28-26 | Initiated | Barclays | Overweight |
| Jan-06-26 | Downgrade | Wolfe Research | Outperform → Peer Perform |
| Nov-05-25 | Upgrade | Cantor Fitzgerald | Neutral → Overweight |
| Nov-03-25 | Upgrade | BofA Securities | Underperform → Neutral |
| Oct-15-25 | Initiated | Truist | Buy |
| Sep-04-25 | Resumed | H.C. Wainwright | Buy |
| Feb-28-25 | Upgrade | B. Riley Securities | Neutral → Buy |
| Feb-27-25 | Reiterated | H.C. Wainwright | Buy |
| Jun-28-24 | Initiated | Cantor Fitzgerald | Neutral |
| Jun-11-24 | Initiated | Wolfe Research | Outperform |
| Apr-22-24 | Initiated | BofA Securities | Underperform |
| Mar-15-24 | Upgrade | B. Riley Securities | Sell → Neutral |
| Mar-06-24 | Initiated | Citigroup | Buy |
| Feb-26-24 | Downgrade | B. Riley Securities | Neutral → Sell |
| Dec-20-22 | Reiterated | Oppenheimer | Outperform |
| Dec-19-22 | Reiterated | H.C. Wainwright | Buy |
| Dec-19-22 | Reiterated | Piper Sandler | Overweight |
| Dec-19-22 | Upgrade | Raymond James | Underperform → Mkt Perform |
| Jul-08-22 | Downgrade | B. Riley Securities | Buy → Neutral |
| Oct-07-21 | Initiated | Jefferies | Buy |
| Aug-06-21 | Upgrade | BMO Capital Markets | Market Perform → Outperform |
| May-20-21 | Resumed | Goldman | Buy |
| Nov-24-20 | Resumed | Evercore ISI | Outperform |
| Nov-06-20 | Reiterated | H.C. Wainwright | Buy |
| Jul-31-20 | Initiated | Piper Sandler | Overweight |
| Jun-05-20 | Initiated | BMO Capital Markets | Market Perform |
| May-05-20 | Initiated | Chardan Capital Markets | Buy |
| Jan-30-20 | Initiated | Canaccord Genuity | Buy |
| Jan-09-20 | Upgrade | UBS | Neutral → Buy |
| Nov-07-19 | Reiterated | H.C. Wainwright | Buy |
| Jun-25-19 | Initiated | Stifel | Hold |
| Jun-10-19 | Upgrade | B. Riley FBR | Neutral → Buy |
| Feb-28-19 | Reiterated | H.C. Wainwright | Buy |
| Feb-22-19 | Initiated | SVB Leerink | Outperform |
| Jan-23-19 | Initiated | UBS | Neutral |
| Dec-14-18 | Initiated | Wolfe Research | Outperform |
| Dec-12-18 | Initiated | B. Riley FBR | Neutral |
| Nov-19-18 | Downgrade | Raymond James | Mkt Perform → Underperform |
| Nov-16-18 | Upgrade | Evercore ISI | In-line → Outperform |
| Sep-04-18 | Initiated | Citigroup | Buy |
| Aug-06-18 | Downgrade | Goldman | Buy → Neutral |
| Jun-28-18 | Initiated | Raymond James | Mkt Perform |
View All
Madrigal Pharmaceuticals Inc Stock (MDGL) Latest News
Fed Watch: What is the dividend yield of Madrigal Pharmaceuticals Inc2026 Market Overview & Growth Oriented Trading Recommendations - baoquankhu1.vn
Dip Buying: Is Madrigal Pharmaceuticals Inc stock good for income investors2026 Intraday Action & Consistent Profit Focused Trading Strategies - baoquankhu1.vn
Breakouts Watch: Can Madrigal Pharmaceuticals Inc weather a recession2026 Sector Moves & Community Verified Watchlist Alerts - baoquankhu1.vn
Madrigal Pharmaceuticals Grants Inducement Awards to New Employees - National Today
What makes Madrigal Pharma (MDGL) one of the shorted biotech stocks to buy - MSN
Madrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Rheos Capital Works Inc. Reduces Stake in Madrigal Pharmaceuticals, Inc. $MDGL - MarketBeat
Winners Losers: Is now the right time to enter Madrigal Pharmaceuticals IncQuarterly Earnings Summary & Daily Stock Trend Watchlist - baoquankhu1.vn
Cantor Fitzgerald Upgrades Madrigal Pharmaceuticals (MDGL) - MSN
Capricorn Fund Managers Ltd Buys New Stake in Madrigal Pharmaceuticals, Inc. $MDGL - MarketBeat
Madrigal outlines robust 2026 net sales growth and expanding pipeline amid 50% MASH market surge - MSN
MDGL Financials: Revenue Breakdown, Margins & Competitor Comparison - Intellectia AI
Toth Financial Advisory Corp Makes New $1.17 Million Investment in Madrigal Pharmaceuticals, Inc. $MDGL - marketbeat.com
Madrigal Pharmaceuticals Grants Equity Awards to New Employees Under 2025 Inducement Plan - MSN
MDGL stock surges most in a month on Eli Lilly buyout speculation - MSN
Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) Given Average Recommendation of "Moderate Buy" by Analysts - MarketBeat
Madrigal Pharmaceuticals to Present at Morgan Stanley Global Health Care Conference - MSN
Madrigal grants equity awards to seven new employees - MSN
Barclays Maintains Madrigal Pharmaceuticals(MDGL.US) With Buy Rating, Maintains Target Price $964 - Moomoo
The $578 Billion Regenerative Medicine Market Has a Manufacturing Problem. One Company Just Solved the First Step - Benzinga
Why Madrigal Pharmaceuticals (MDGL) Is Up 14.1% After Expanding Its MASH Franchise Beyond Rezdiffra - Sahm
Madrigal Soars 5.87% on Strong Analyst Momentum and Institutional Shifts—Where to Now? - bitget.com
Hennion & Walsh Asset Management Inc. Sells 4,684 Shares of Madrigal Pharmaceuticals, Inc. $MDGL - MarketBeat
MDGL Technical Analysis | Trend, Signals & Chart Patterns | MADRIGAL PHARMACEUTICALS INC (NASDAQ:MDGL) - ChartMill
Understanding Momentum Shifts in (MDGL) - Stock Traders Daily
Madrigal Pharmaceuticals grants equity awards to 20 new employees - MSN
Madrigal Pharmaceuticals (MDGL) surged on strong sales of its Rezdiffra drug - MSN
Assenagon Asset Management S.A. Acquires New Stake in Madrigal Pharmaceuticals, Inc. $MDGL - MarketBeat
Madrigal Pharmaceuticals stock dips after team presence at Liver Connect Conference sees doubled attendance - Traders Union
Madrigal Reports $212.8M in Q2 Rezdiffra Sales, Expands Global Pipeline and Secures $500M Financing - MSN
Loss Report: What are analysts price targets for Madrigal Pharmaceuticals Inc2026 Bull vs Bear & Technical Pattern Based Signals - baoquankhu1.vn
MDGL Stock Surges Most In A Month On Eli Lilly Buyout Speculation - Stocktwits
Madrigal Pharmaceuticals (MDGL) Surged on Strong Sales of Its Rezdiffra Drug - Insider Monkey
Vanguard (MDGL) files amendment; reports 0 shares after Jan 12, 2026 realignment - Stock Titan
Madrigal (MDGL) Surges 12.3%: Is This an Indication of Further Gains? - Yahoo Finance
Is It Too Late To Consider Madrigal Pharmaceuticals (MDGL) After Recent Share Price Surge? - Yahoo Finance
Madrigal Pharmaceuticals gains amid renewed takeover speculation - MSN
Rezdiffra Shows Promise as Madrigal’s Liver Drug Garners Positive Results - StocksToTrade
Madrigal Pharmaceuticals (NASDAQ:MDGL) Trading 11.7% HigherShould You Buy? - marketbeat.com
Madrigal Surges 11.66%: A Volatile Breakout Defies Sector Stagnation as Bulls Test $572 - Bitget
Madrigal Grants Equity Awards to Seven New Employees - MyChesCo
Madrigal Pharmaceuticals, Inc. $MDGL Stock Position Raised by Peak Financial Advisors LLC - MarketBeat
Fundamentals Check: Is Madrigal Pharmaceuticals Inc benefiting from innovation trends2026 Momentum & Consistent Return Strategy Ideas - baoquankhu1.vn
JPMorgan Chase & Co. Sells 8,030 Shares of Madrigal Pharmaceuticals, Inc. $MDGL - MarketBeat
Aug Selloffs: How correlated is Madrigal Pharmaceuticals Inc to the S P5002026 Price Momentum & AI Powered Market Trend Analysis - baoquankhu1.vn
Madrigal Pharmaceuticals Inc Stock (MDGL) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.00%
1.95%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):